Skip to main content

Health condition

Non-Hodgkin lymphoma, from painless swelling to a clear treatment plan.

A diverse group of lymphatic cancers, ranging from slow-growing disease that can simply be watched to aggressive subtypes that need prompt chemoimmunotherapy. Subtype and stage drive everything.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE NG52, British Society for Haematology and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance including R-CHOP regimens, CAR-T access routes and haemato-oncology MDT pathways.

Key facts

Non-Hodgkin lymphoma at a glance.

The essentials, in plain English - what it is, how it differs from Hodgkin lymphoma, and how it’s treated in the UK today.

  • What it is

    A diverse group of cancers arising in the lymphatic system, split broadly into slow-growing (indolent) and fast-growing (aggressive) subtypes.

  • Versus Hodgkin

    Diagnosed by the absence of Reed-Sternberg cells on biopsy - the feature that separates it from Hodgkin lymphoma.

  • Common indolent type

    Follicular lymphoma - often watched rather than treated immediately, sometimes for years.

  • Common aggressive type

    Diffuse large B-cell lymphoma (DLBCL) - needs prompt chemoimmunotherapy but is often curable.

  • Essential test

    Excision lymph node biopsy - needle sampling alone rarely gives enough tissue to subtype the lymphoma properly.

  • Backbone treatment

    R-CHOP (rituximab plus chemotherapy) for aggressive disease, with radiotherapy, CAR-T or transplant options in specific situations.

Why this guide matters

Subtype and stage decide everything.

Non-Hodgkin lymphoma is not one disease but a family of them. The three points below shape everything else on this page.

  • It is a spectrum, not one illness

    Some subtypes grow so slowly they can be watched for years; others need urgent treatment within weeks of diagnosis.

  • Biopsy quality matters enormously

    Getting a full excision biopsy, not just a needle sample, is what allows accurate subtyping and the right treatment choice.

  • Many aggressive cases are curable

    Diffuse large B-cell lymphoma, the most common aggressive subtype, is often cured outright with modern chemoimmunotherapy.

How the diagnosis is made

From swollen glands to a confirmed plan.

The steps a UK GP and haemato-oncology team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Unexplained lymphadenopathy

    Persistent, painless lymph node swelling lasting more than six weeks triggers an urgent NICE NG52 pathway referral.

  2. 02

    Assessing

    History and B symptoms

    Fever, drenching night sweats, unexplained weight loss, fatigue and itching are actively asked about - these shape both urgency and staging.

  3. 03

    Assessing

    Baseline blood tests

    FBC, LDH, renal and liver function, and inflammatory markers - LDH in particular can flag more aggressive or bulky disease.

  4. 04

    Confirming

    Excision lymph node biopsy

    The essential test - a whole node (not just a needle sample) is removed so pathologists can subtype the lymphoma accurately.

  5. 05

    Confirming

    CT or PET-CT staging

    Full-body imaging maps every site of disease above and below the diaphragm and checks for extranodal spread.

  6. 06

    Confirming

    Bone marrow biopsy

    Used in most confirmed cases to check whether the marrow is involved, which affects staging and treatment choice.

  7. 07

    Planning

    Haemato-oncology MDT

    A specialist multidisciplinary team confirms subtype, stage and fitness, then agrees a personalised treatment plan.

Typical timeline: urgent referral to a confirmed subtype and stage within two to four weeks.

Symptoms

What non-Hodgkin lymphoma actually looks like.

Painless swollen glands are the classic sign, but B symptoms and extranodal involvement matter too. And the features that mean it’s time to act fast.

  • Painless lymphadenopathy

    The most common presenting feature - firm, rubbery, non-tender swelling in the neck, armpit or groin.

  • B symptoms

    Unexplained fever, drenching night sweats and weight loss of more than ten per cent - a marker of more active disease.

  • Fatigue

    Persistent tiredness out of proportion to activity, sometimes the earliest symptom noticed.

  • Gastrointestinal involvement

    Abdominal pain, bloating, altered bowel habit or bleeding when lymphoma affects the gut wall.

  • Skin involvement

    Lumps, plaques or unusual rashes when lymphoma affects the skin directly.

  • Neurological symptoms

    Headache, confusion or focal weakness can signal rare central nervous system involvement.

  • Splenomegaly

    An enlarged spleen felt on examination, sometimes causing early fullness or discomfort.

  • Red flag - rapid enlargement

    Fast-growing nodes, breathlessness or superior vena cava symptoms need same-day assessment.

Treatment

How non-Hodgkin lymphoma is treated in the UK.

Watchful waiting for indolent disease, R-CHOP for aggressive subtypes - and CAR-T or transplant when standard treatment isn’t enough.

  • Watchful waiting

    Standard for asymptomatic indolent lymphoma such as low-grade follicular disease - active monitoring without immediate treatment.

  • Chemoimmunotherapy (R-CHOP)

    Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisolone - the standard for aggressive or symptomatic disease.

  • Rituximab maintenance

    Ongoing antibody therapy after initial treatment in some indolent subtypes to extend remission.

  • Radiotherapy

    Used for localised, early-stage disease or to consolidate a response after chemoimmunotherapy.

  • CAR-T cell therapy

    Genetically modified immune cells for relapsed or refractory aggressive lymphoma, delivered in specialist centres.

  • Stem cell transplant

    Autologous or allogeneic transplant for eligible patients with relapsed disease after intensive chemotherapy.

  • Targeted and novel agents

    Bruton tyrosine kinase inhibitors, bispecific antibodies and other newer drugs for specific subtypes and relapsed disease.

  • Haemato-oncology MDT review

    Every treatment plan is agreed and reviewed by a specialist commissioned multidisciplinary team throughout care.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your haemato-oncology team knows your subtype, stage and history and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Suspected cancer: recognition and referral (NG12) and Haematological cancers overview (NG52).

  • British Society for Haematology. Guidelines on the diagnosis and management of non-Hodgkin lymphoma.

  • NHS England. Specialised commissioning for haemato-oncology services, including CAR-T therapy.

  • World Health Organization. Classification of tumours of haematopoietic and lymphoid tissues.

Red flags

When lymphoma needs urgent attention.

Most care happens on a planned pathway. These are the situations that can’t wait - and where emergency or same-day assessment is needed.

  • Rapidly enlarging mass

    Nodes or a mass doubling in size over days to weeks suggests aggressive disease needing urgent specialist review.

  • Superior vena cava obstruction

    Facial swelling, breathlessness lying flat or distended neck veins from a bulky chest mass is a same-day emergency.

  • Spinal cord compression

    New back pain with leg weakness, numbness or bladder or bowel disturbance needs immediate imaging and specialist input.

  • Tumour lysis syndrome risk

    Bulky, fast-growing disease before treatment starts carries a risk of dangerous metabolic disturbance - closely monitored on starting chemotherapy.

  • Neutropenic sepsis

    Fever during chemotherapy is a medical emergency - same-day assessment and antibiotics, whatever the time of day.

  • Central nervous system involvement

    New headache, confusion, seizures or focal neurological signs need urgent imaging and specialist assessment.

  • Airway compromise

    Stridor or severe breathlessness from a mediastinal mass is a critical emergency requiring immediate hospital care.

  • Significant unexplained weight loss

    Loss of more than ten per cent of body weight alongside lymphadenopathy strengthens the case for urgent referral.

  • Persistent unexplained fever

    Fever lasting more than two weeks without an infective cause, especially with night sweats, warrants prompt investigation.

Living with it

A treatable condition, with a clear pathway.

Four things that make the biggest difference through diagnosis and treatment - understanding watchful waiting, lining up support, taking infection risk seriously and staying with follow-up.

A quiet reminder

A diagnosis is not a single outcome.

Subtype and stage vary enormously - many people with non-Hodgkin lymphoma are treated successfully and return to normal life.

  1. 01 Monitor

    Watchful waiting is a strategy, not a wait

    For indolent lymphoma, active monitoring with regular reviews is a deliberate, evidence-based choice - not a delay in care.

  2. 02 Support

    Line up practical and emotional support

    Treatment can be intensive - macmillan-style support, workplace adjustments and counselling all help through the course of care.

  3. 03 Infection

    Take neutropenic precautions seriously

    During chemotherapy, avoid known infection risks and seek same-day help for any fever - do not wait it out.

  4. 04 Follow-up

    Long-term follow-up matters

    After treatment, scheduled reviews watch for relapse and manage late effects of chemotherapy or radiotherapy.

Frequently asked

Everything we get asked about non-Hodgkin lymphoma.

Quick answers on subtypes, biopsy, watchful waiting, R-CHOP and CAR-T.

  • What is non-Hodgkin lymphoma?

    A diverse group of cancers of the lymphatic system, distinct from Hodgkin lymphoma by the absence of Reed-Sternberg cells on biopsy. Subtypes range from slow-growing (indolent), such as follicular lymphoma, to fast-growing (aggressive), such as diffuse large B-cell lymphoma.

  • How is it different from Hodgkin lymphoma?

    The two are distinguished under the microscope - non-Hodgkin lymphoma lacks the characteristic Reed-Sternberg cells seen in Hodgkin lymphoma. They also differ in typical patterns of spread, age distribution and treatment approach, although both are managed by specialist haemato-oncology teams.

  • Why is a lymph node biopsy necessary rather than a needle sample?

    Subtyping lymphoma accurately needs enough tissue to study the architecture and cell markers of the node, which a fine needle sample usually cannot provide. An excision biopsy - removing the whole node - is considered essential under NICE NG52 pathways.

  • What does watchful waiting mean in practice?

    For asymptomatic, slow-growing lymphoma such as low-grade follicular disease, evidence shows that starting treatment immediately does not improve survival compared with active monitoring. Regular clinical review and blood tests continue until treatment is actually needed.

  • What is R-CHOP and who needs it?

    R-CHOP combines the antibody rituximab with four chemotherapy drugs - cyclophosphamide, doxorubicin, vincristine and prednisolone. It is the standard treatment for aggressive subtypes such as diffuse large B-cell lymphoma, and is often curative.

  • When is CAR-T cell therapy considered?

    CAR-T is generally reserved for relapsed or refractory aggressive lymphoma that has not responded to, or has come back after, standard chemoimmunotherapy. It involves genetically modifying a patient’s own immune cells and is delivered only in specialist commissioned centres.

Related content

Keep reading.